Supreme Court Lets Merck Loss In Fosamax Case Stand
In a setback for Merck & Co., the U.S. Supreme Court has rejected the company's appeal of a decision that shaved a decade off the patent for blockbuster osteoporosis drug Fosamax....To view the full article, register now.
Already a subscriber? Click here to view full article